Inhibition of BCR signaling in the LN correlates with nodal response. (A-B) BCR gene signature scores are shown for patients with mutated (n = 9) and unmutated IGHV (n = 14). Comparisons within patients are by paired Student t test, whereas comparisons between mutational subgroups are by an unpaired Student t test. (A) Comparison of baseline BCR scores in CLL cells sampled from the peripheral blood (PB) and the matching lymph node (LN). (B) Comparison of pretreatment and day 2 BCR scores in LN core biopsies. (C) Correlation between percent reduction in lymphadenopathy and percent reduction in BCR signaling on day 2 in the lymph node. Gray squares represent patients who did not achieve a 50% reduction in lymphadenopathy after 2 months on treatment. Dashed lines represent the 50th percentile. (D) Percent reduction in lymphadenopathy in patients divided by the degree of reduction in the BCR signature score. Comparison is by Student t test.